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Background: The objective of this study was to characterize real-world treatment patterns in the prescription of
antipsychotic polypharmacy (≥2 concurrent antipsychotics) compared with antipsychotic monotherapy for patients
with schizophrenia.
Methods: This study was a retrospective claims-based analysis of patients (aged 13–64 years) with schizophrenia
belonging to an employer-based health plan. Duration of therapy was measured as the number of treatment days
over one year following the initial date of antipsychotic therapy. Discontinuation was defined as a 90-day gap in
antipsychotic treatment (or in at least one antipsychotic for the polypharmacy group). Logistic regression analyses
were used to predict discontinuation within one year. Ordinary Least Squares (OLS) regressions were used to predict
duration of therapy (by type of therapy) when controlling for gender, region, number of somatic and psychiatric
comorbidities, Deyo-Charlson comorbidity score, and number of psychiatric and somatic medications.
Results: Of the 4,156 patients, 3,188 received monotherapy and 968 received polypharmacy. Mean age was
40 years (37.8 years for polypharmacy vs 40.3 years for monotherapy, p < 0.001). Within one year, 77% of the
polypharmacy group and 54% of the monotherapy group discontinued treatment. The average duration of therapy
was 163 [SD = 143] days in the polypharmacy group vs 253 [SD = 147] days in the monotherapy group. In both
cohorts, patients <25 years had a higher frequency of discontinuations than those ≥26 years. Age and
polypharmacy were independent predictors of treatment duration and discontinuation prior to one year.
Conclusions: One quarter of patients with schizophrenia received antipsychotic polypharmacy. Discontinuation was
higher in the polypharmacy group. Age and polypharmacy were significant predictors of treatment discontinuation.
Keywords: Schizophrenia, Polypharmacy, Claims-based analysis, Patterns of useBackground
Antipsychotics have limited impact on the negative
symptoms of schizophrenia and are not consistently or
fully effective against positive symptoms [1,2]. This can
lead to poor patient outcomes, including relapse and
hospitalization [3,4]. Even with adequate antipsychotic
treatment, many patients with schizophrenia continue to
experience symptoms: according to the W-SOHO study,
15–39% experience a persistent symptomatic course and
14–21% of those experiencing remission subsequently
relapse within a three-year period [5]. Current clinical prac-
tice commonly involves combining antipsychotics to im-
prove treatment of patients with suboptimally controlled* Correspondence: kathleen.villa@jazzpharma.com
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unless otherwise stated.symptoms of schizophrenia, despite the lack of robust evi-
dence for this approach, the increased risk of side effects,
and the cost implications [6-9]. Polypharmacy prevalence
rates vary widely from 2–70% [10-21] depending on study
design, patient population, diagnosis, and geographical re-
gion, with a median of 19.6% of patients worldwide receiv-
ing multiple antipsychotics [22]. Polypharmacy prevalence
is expected to continue to rise as more antipsychotics
become available and as physicians become more familiar
with the practice [11,22,23].
Evidence supporting polypharmacy is lacking, how-
ever. The majority of published studies regarding the use
of two or more antipsychotics are limited to combina-
tions with clozapine – which held the promise of im-
proving effectiveness by taking advantage of medications
with different mechanisms of action and side-effecttd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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ior efficacy of polypharmacy [10,24,27-29]. Initially, it was
believed that combining antipsychotics at lower doses
could improve effectiveness without increasing the risk of
treatment-related side effects associated with escalating
doses of single agents [10]. However, polypharmacy has
been associated with excessive total antipsychotic doses,
which may increase dose-related side effects, the risk for
drug interactions, and complicated dosing regimens that
may lead to treatment discontinuation [10,16,28,29]. In
the absence of clear benefit, treatment guidelines largely
discourage the use of antipsychotic polypharmacy for the
treatment of schizophrenia [30]. Polypharmacy is recom-
mended for limited situations in which the patient has
failed at least three trials of antipsychotic monotherapy of
adequate dose and duration, including clozapine [29].
Along with the paucity of research regarding the effi-
cacy of polypharmacy, little is known about the charac-
teristics of patients who receive polypharmacy versus
monotherapy for the treatment of schizophrenia. To fill
these gaps in current knowledge, this study characterized
real-world treatment patterns, including medication
switching and discontinuation, in patients with schizo-
phrenia treated with antipsychotic monotherapy versus
those treated with polypharmacy.
Methods
This retrospective cohort analysis included patients se-
lected from the HealthCore Integrated Research Envir-
onment (HIRE), a database of medical, laboratory, and
pharmacy claims of commercially insured patients. The
HIRE contains administrative claims data from 14 major
commercial health plans across the United States, repre-
senting 45 million lives.
As a non-interventional, observational analysis, no pa-
tients were directly involved in the study. The study was
conducted in compliance with state and federal laws,
including the Health Insurance Portability and Account-
ability Act (HIPAA) of 1996.
A chart review was included in this study and approval
for a complete waiver of HIPAA authorization was
granted by a central Institutional Review Board (Quorum
Review IRB, waiver #26699) prior to chart collection. All
claims were from a limited dataset with anonymized
patient information.
Patients
Patients between the ages of 13 and 64 years who had two
or more claims for schizophrenia (International Classifica-
tion of Diseases, 9th edition code 295.xx) from January 1,
2007 through to April 30, 2010 were included in the study.
The younger patients were included in order to be able to
describe the treatment patterns not only for chronic
schizophrenia patients, but also for those who are at theearliest stages of their diagnosis and disease. Patients were
followed for one year subsequent to the first claim for
schizophrenia (the index date).
Antipsychotic medications were identified from phar-
macy claims closest to the index date (±90 days). All
first-generation (FGA) and second-generation (SGA) an-
tipsychotics were included. Patients with a prescription
for an FGA and/or SGA within 90 days before or after
the index date were stratified by type of therapy into the
monotherapy or polypharmacy cohorts. The first of
these prescriptions was defined as the index medication.
Monotherapy was defined as a single antipsychotic
medication, whereas polypharmacy was defined as hav-
ing two or more antipsychotics within a 45-day period.
Short-acting antipsychotics given by injection for acute
treatment were excluded to eliminate the possibility of
mis-categorizing patients taking medications in an in-
patient setting. Long-acting injections were not included
because we found their use to be low in the claims (<2%
overall, data not shown).
From the list of all schizophrenia patients included in
the study, a random sample of 200 was targeted for
medical record review. Patients were required to have
documented schizophrenia in their medical record.
Outcome measures
Because clinical outcome measures are not available in
administrative claims data, the primary outcome meas-
ure used in this analysis was duration of therapy, mea-
sured over one year following the date antipsychotic
treatment was initiated. Treatment duration was defined
as the number of days without a 90-day gap in treat-
ment. Discontinuation was defined as a 90-day gap in
antipsychotic therapy prior to the end of the one year
follow-up period. In the polypharmacy group, discon-
tinuation was defined as a 90-day gap in at least one of
the antipsychotic medications during follow-up.
Secondary outcomes included the type and number of
psychiatric and somatic comorbidities during the one
year follow-up period. Psychiatric comorbidities included
depression, anxiety, bipolar, schizoaffective, attention-
deficit and personality disorders. Analysis of somatic
comorbidities included the Deyo-Charlson Comorbidity
Index (DCI) score [31] and the proportion of patients
with claims for cardiovascular diseases, cerebrovascular
disease, diabetes, hyperglycemia, or hyperlipidemia. Con-
comitant psychiatric medications other than antipsy-
chotics, including antidepressants, anxiolytics, hypnotics
and sedatives, mood stabilizers, and stimulants, were re-
corded. The type and number of somatic medications,
including lipid-modifying agents, anti-diabetic agents,
anti-Parkinson disease and movement disorder medica-
tions, cardiovascular agents, and anti-obesity drugs were
also collected.
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claims cohort was selected for medical chart review to
estimate schizophrenia severity because this is not avail-
able in claims data. Severity within the sub-sample was
determined from physician documentation in the charts
and described as mild, moderate or severe. Due to the
small number of patients with documented schizophre-
nia severity, comparisons between polypharmacy and
monotherapy groups were descriptive only.
Statistical analysis
Measures were described as means (± standard deviation
[SD]) for continuous variables, and frequencies for cat-
egorical variables. Differences in mean length of therapyTable 1 Patient characteristics at baseline (6 months pre-inde
Characteristic Tot
(N =
Length of follow-up, days (mean, SD) 993
Gender, n (%)
Male 220
Age at index date, years (mean, SD) 40 (






Attention deficit disorder 114
Substance use disorder 83 (
Psychiatric medications, n (%)
Antidepressants 201
Sedatives or hypnotics 162
Mood stabilizers 107
Anti-anxiety medications 926
Stimulants and ADHD medications 40 (
Mean (SD) Deyo-Charlson Comorbidity Index Score (range 0–16) 0.6





Anti-Parkinson agents 60 (
Random sample of patients with baseline disease severity data




ADHD = attention deficit hyperactivity disorder; SD = standard deviation.
aPolypharmacy vs monotherapy.were compared using t tests, and χ2 tests were used to
compare the proportion of patients discontinuing treat-
ment and the prevalence of comorbidities. Ordinary
Least Squares (OLS) regression was used to predict the
length of therapy (by type of antipsychotic therapy regi-
men), when controlling for gender, region, number of
somatic and psychiatric comorbidities, DCI score, and
the number of psychiatric and somatic medications.
Results
Patient characteristics
A total of 4,156 patients were included in the study. Of
these, 3,188 were in the monotherapy cohort and 968 were








.5 (391.8) 989.3 (393.8) 999.3 (397.1) .488
6 (53.1) 1,710 (53.6) 496 (51.2) .190
13.7) 40.3 (13.6) 37.8 (13.6) <.001
0 (26.2) 806 (25.3) 284 (29.3) .012
(23.8) 786 (24.7) 205 (21.2) .026
(10.6) 336 (10.5) 105 (10.8) .786
(5.9) 190 (6.0) 57 (5.9) .934
(3.1) 94 (2.9) 34 (3.5) .374
(2.7) 83 (2.6) 31 (3.2) .318
2.0) 59 (1.9) 24 (2.5) .221
6 (48.5) 1516 (47.6) 500 (51.7) .025
3 (39.1) 1051 (33.0) 572 (40.9) <.001
3 (25.8) 794 (24.9) 279 (28.8) .015
(22.3) 678 (21.3) 248 (25.6) .004
1.0) 32 (1.0) 8 (0.8) .621
(1.0) 0.6 (1.0) 0.6 (0.9) .546
(15.0) 490 (15.4) 133 (13.7) .213
(12.1) 408 (12.8) 94 (9.7) .010
(10.1) 310 (9.7) 108 (11.2) .194
(8.6) 275 (8.6) 83 (8.6) .960
1.4) 37 (1.2) 23 (2.4) .005
20.7) 22 (23.2) 3 (11.5)
25.6) 25 (26.3) 6 (23.1)
53.7) 48 (50.5) 17 (65.5)
Table 2 Index antipsychotic therapies
Therapy Total N = 4,156
n (%)
Patients on monotherapy (% of total) 3,188 (76.7)
Number of patients by type of antipsychotic







Other second-generation antipsychotic 57 (1.8)
First-generation antipsychotic 427 (13.4)
Total on polypharmacy (% of total) 968 (23.3)
Number of patients by type of antipsychotic
polypharmacy combinations (% of polypharmacy)
Combinations with first-generation antipsychotics 257 (26.5)
Combinations with olanzapine 216 (22.3)
Combinations with risperidone 210 (21.7)
Combinations with other second-generation
antipsychotics
186 (19.2)
Combinations with clozapine 99 (10.2)
Top 5 polypharmacy combinations
Quetiapine and risperidone 96 (9.9)
Quetiapine and aripiprazole 94 (9.7)
Quetiapine and first-generation antipsychotic 83 (8.6)
Aripiprazole and risperidone 65 (6.7)
Aripiprazole and olanzapine 65 (6.7)
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polypharmacy group).The mean age was 40 years, with
patients in the polypharmacy group significantly younger
than those in the monotherapy group (37.8 vs. 40.3 years,
respectively, p < 0.001).
At baseline, 26.2% of the overall patient population
had comorbid depression (29.3% and 25.3% in the poly-
pharmacy and monotherapy cohorts, respectively; p =
0.012) and 23.8% had comorbid schizoaffective disorders
(21.2% and 24.7%, respectively; p = 0.026). There was no
statistical difference in the DCI score between the two
groups at baseline. Patients in the polypharmacy group
had significantly higher use of concomitant psychiatric
medications (other than antipsychotics) at baseline com-
pared with the monotherapy group, notably antidepres-
sants (51.7 vs. 47.6%), sedatives (40.9 vs. 33.0%), mood
stabilizers excluding antipsychotics [27,32,33] (28.8 vs.
24.9%), and anxiolytics (25.6 vs. 21.3%). The monother-
apy group had a statistically higher proportion of pa-
tients with claims for anti-hypertensive agents compared
with the polypharmacy group (12.8 vs. 9.7%; p = 0.010).
Claims for anti-Parkinson agents were higher in the
polypharmacy group compared to the monotherapy
group (2.4 vs. 1.2%; p = 0.005) (Table 1).
In the sample of 200 patient charts selected for assess-
ment of schizophrenia severity, 188 patients were receiv-
ing antipsychotic medications. Of these 188 patients, 121
patients had a severity rating within 30 days of the index
date. Among those, a higher proportion of patients in the
polypharmacy cohort were rated as having severe disease
compared with those in the monotherapy cohort (65.5 vs.
50.5%), whereas, more patients in the monotherapy group
were rated as having mild disease than those in the poly-
pharmacy group (23.2 vs. 11.5%) (Table 1).
Index antipsychotic use
Table 2 outlines the specific antipsychotics and anti-
psychotic combinations that were used in the two
groups. For the 76.7% of patients who were on mono-
therapy, the most frequently used antipsychotic was
risperidone (24%). Among the 23.3% of patients in the
polypharmacy cohort, 63.2% of the combinations in-
cluded olanzapine, risperidone, or another SGA other
than clozapine. The most commonly used combination
was quetiapine plus risperidone (9.9%). Only 10.2% of
the polypharmacy combinations included clozapine.
Slightly more than a quarter of the polypharmacy com-
binations (26.5%) included an FGA. In comparison, only
13.4% of those in the monotherapy cohort received an
FGA as index therapy.
Discontinuation and duration of therapy
A higher proportion of patients in the polypharmacy co-
hort discontinued index treatment prior to the end ofthe one year follow-up period compared with the mono-
therapy group (Figure 1). Overall, 77% of those in the
polypharmacy group discontinued at least one of their
index antipsychotics within one year, whereas 54% of
those in the monotherapy group discontinued their
index medication within one year. A greater proportion
of patients in the polypharmacy group discontinued
therapy compared with those receiving monotherapy
when all age groups were considered. In both the mono-
therapy and polypharmacy cohorts, patients younger
than 25 years had a higher frequency of treatment dis-
continuation prior to one year than those 26 years and
older (Figure 1).
The average duration of therapy (i.e., without a gap of
90 days or more) was significantly greater for patients in
the monotherapy cohort than those in the polypharmacy
cohort (252.7 [SD = 147.4] vs 163.8 [SD = 143.4] days;
p < 0.01; Data not shown).
Among the patients included in the chart review sample,
those with greater disease severity had a higher frequency
of treatment discontinuation within one year compared
Figure 1 Percentage of patients, by age, who discontinueda within one year follow-up. aFor polypharmacy patients, discontinuation was
defined as a 90-day treatment gap in at least 1 index antipsychotic.
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(68 vs. 46%; Data not shown).
In multiple regression analyses, both age and use of
polypharmacy were independent predictors of length of
therapy defined as the number of days on the index
medication (Table 3). Additionally, receiving two or
more psychiatric medications (that were not antipsy-
chotics) was also independently associated with a shorter
duration of antipsychotic therapy (−13 days; p < 0.047).
After discontinuing antipsychotic therapy, 10.3% of
patients in the monotherapy cohort restarted their index









Number of psychiatric medications post-index (reference = 0)
One
Two or more





aCovariates not shown include plan region, number of somatic comorbidities, and Dswitched to a different antipsychotic (Table 4). Commen-
surate with its use as a treatment reserved for patients who
have failed to respond to other antipsychotics, clozapine
had the lowest proportion of patients (4.5%) switching
medications. Among the more commonly used antipsy-
chotics, the patients who switched least often were those
taking aripiprazole (8.8%) (Table 5). In addition, aripipra-
zole was the most common second medication among pa-
tients in the monotherapy cohort who switched treatment
(Figure 2). Patients receiving an SGA as index therapy but
later switched tended to receive a different SGA as second-
line therapy. Among patients who received an FGA as thength of therapy
95% Confidence interval
Coef. (lower – upper) p-Value
−106.638 (−117.179 – −96.096) <.001
−1.700 (−10.914 – 7.514) .718
1.582 (1.198 – 1.965) <.001
−9.402 (−19.946 – 1.142) .081
−38.278 (−52.526 – −24.031) <.001
−67.391 (−87.620 – −47.163) <.001
−4.376 (−17.546 – 8.794) .515
−12.682 (−25.211 – −0.153) .047
20.108 (8.237 – 31.980) .001
13.279 (−1.724 – 28.283) .083
218.211 (197.930 – 238.492) <.001
0.148
eyo-Charlson comorbidity index score.
Table 4 Antipsychotic medication status after
discontinuation among patients on monotherapy who




Patients who discontinued prior to 12 months, n (%) 1706 (53.5)
Patients who restarted medication after 90 day gap in
treatment, n (%)
317 (10.3)
Mean time to restart, days (SD) 182.7 (59.3)
Patients who switched medications, n (%) 439 (13.8)
Average time to first switch, days (mean, SD) 166.9 (100.7)
Number of switches, n (%)
One 356 (81.1)
Two 58 (13.2)
Three or more 25 (5.7)
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to another FGA.
Among patients in the polypharmacy cohort who
discontinued at least one of their index antipsychotics,
39.1% switched to monotherapy. Of those who switched
to monotherapy, 21.1% remained on one of their index
antipsychotics while 18.0% switched to a different agent
(Table 6). Of the 17.2% of patients who remained on a
polypharmacy regimen, 8.9% received a combination
that included one of their index medications; 8.3% were
switched to a polypharmacy regimen that included dif-
ferent medications. A substantial proportion of patients
in the polypharmacy group who discontinued index
therapy did not receive antipsychotics (43.8%) for the
remainder of the follow-up period.
Discussion
In this real-world cohort analysis, 23% of patients with
schizophrenia were prescribed two or more antipsychotic
medications. Although prevalence rates in previous studiesTable 5 Overall rate of switch during one year follow-up
by index monotherapy
Index therapy Patients switching from







Other second-generation antipsychotic 11 (19.3)
First-generation antipsychotic 68 (15.9)
Total 439 (13.8)ranged from 2% to 70% [10-21], our findings are consist-
ent with a worldwide median of 19.6% [21,22]. It is ex-
pected that the rates reported in our claims analysis would
be lower than those reported elsewhere given that the
database consisted of patients with schizophrenia who
were members of employer-based health plans. Such
patients would be expected to have lower schizophrenia
severity as they would be required to maintain either
steady employment or family relationships to retain health
plan eligibility.
We found the highest polypharmacy rates among pa-
tients with more severe schizophrenia. Similarly, medical
chart review suggested that more severe schizophrenia was
seen in patients receiving polypharmacy. Among the youn-
gest patients, whose early course may signal greater schizo-
phrenia severity, polypharmacy rates were higher than
those seen in older patients. It is possible that some pa-
tients using short-term polypharmacy were mis-classified
in our study as receiving polypharmacy, causing slightly
higher percentages than those in other studies. None of the
patients categorized as polypharmacy had fewer than two
concomitant fills. Injectable medications were excluded.
While approximately a quarter of patients receiving
polypharmacy were prescribed a combination that in-
cluded an FGA, the most frequently used combinations
across all classes were combinations of SGAs. An add-
itional examination of the treatment patterns by age
showed that combinations of two FGAs were more fre-
quent among patients in the two oldest age groups,
whereas combinations with SGAs were more common
in the younger age groups. Furthermore, our data show
that patients who were transitioned off monotherapy
were more often prescribed a second antipsychotic to
the one that they had failed, rather than started on two
new medications. Thus, within the older age groups,
treatment patterns were consistent with guidelines that
recommend polypharmacy only after the patient has
failed trials of at least one additional SGA, an FGA, and
finally clozapine. However, in our study population, the
use of clozapine either alone or in combination was low.
Treatment patterns may have differed among age
groups based on timing and availability of newer anti-
psychotics. Still, these data suggest that many physicians
did not wait for patients in younger age groups to fail
multiple types of treatments before moving to an anti-
psychotic polypharmacy regimen. This finding is consist-
ent with previous research showing that physicians tend
to prescribe multiple antipsychotics before exploring the
full dose range of several different single antipsychotic
agents [10,19,33]. Although it is understandable that
physicians want to control severe acute symptoms of
schizophrenia, particularly early in the course of disease,
long-term use of polypharmacy beginning at an early age
may pose additional risk to patients and warrants further
Figure 2 Days to first switch by index medication by medication of most frequent switch among 439 monotherapy patients who
switched antipsychotic therapy during 12-month follow-up. FGA = first-generation antipsychotic; SGA = second-generation antipsychotic.
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safer than switching a patient to an SGA, then to cloza-
pine, but these attitudes may be changing with the grow-
ing body of evidence that SGAs carry their own serious
adverse effects on physical health [34-36]. The use of con-
comitant psychiatric medications was not only high but
also higher among patients in the polypharmacy cohort
than the monotherapy cohort. The high use of benzodiaz-
epines is of concern given the recent findings of morbidity
and mortality links to benzodiazepine use and polyphar-
macy use among patients with schizophrenia [10].Table 6 Antipsychotic switching among patients
receiving polypharmacy who discontinued (90 day gap in
therapy) ≥1 index antipsychotics during one year
follow-up
n (%)
Patients receiving polypharmacya who discontinued ≥1
index medications
745 (77.0)
Antipsychotic medication status after discontinuation
Monotherapy with 1 of the index medications 157 (21.1)
Monotherapy with switch to a new antipsychotic 134 (18.0)
New polypharmacy regimen including 1 of the index
medications
66 (8.9)
New polypharmacy regimen with all new antipsychotics 62 (8.3)
Remained on no antipsychotics 326 (43.8)
an = 968.The discontinuation rate of 77% among patients in the
polypharmacy cohort is high, but consistent with prior
research [34]. The shorter duration of therapy in the
polypharmacy cohort may have been related to concerns
by physicians over the long-term use of two antipsy-
chotics and may have been an intentional strategy. It is
difficult to tease apart non-adherence/persistence on the
part of patients from prescribing decisions made by phy-
sicians in claims. Another limitation of claims analyses is
that we are unable to estimate optimum antipsychotic
dose. The post-medication status of patients who en-
tered the study on polypharmacy suggests a number of
possible circumstances. In keeping with the known chal-
lenges of adherence among patients with schizophrenia,
combinations of antipsychotics, which require more
complex dosing regimens, and the overall higher pill
burden, may make adherence among these patients all
the more difficult [10]. Furthermore, lack of efficacy and
emergence of side effects may also have led treating phy-
sicians to abandon the strategy of polypharmacy. Unfor-
tunately, for patients with severe symptoms that do not
fully remit with current treatments, few alternatives are
yet available.
Conclusions
In a real-world analysis, 23% of patients with schizophre-
nia received treatment with two or more antipsychotic
agents simultaneously. Discontinuation rates were higher
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those receiving monotherapy. Patient age and use of
polypharmacy were independent predictors of length of
therapy over one year of follow-up.
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